Delivering a Complex First-in-Human Study for a Potential Schizophrenia Treatment 

A randomised, blinded, placebo-controlled, single ascending dose (SAD) study and multiple ascending dose (MAD) study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a glutamate receptor enhancer in healthy, adult volunteers. 

View Resource